Volume | 5,824 |
|
|||||
News | - | ||||||
Day High | 1.56 | Low High |
|||||
Day Low | 1.37 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Protagenic Therapeutics Inc | PTIX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
1.47 | 1.37 | 1.56 | 1.37 | 1.35 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
71 | 5,824 | $ 1.45 | $ 8,429 | - | 0.6797 - 2.32 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:00:00 | 194 | $ 1.37 | USD |
Protagenic Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
6.08M | 4.44M | - | 0 | -5M | -1.13 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Protagenic Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical PTIX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.66 | 1.79 | 1.1535 | 1.46 | 3,584 | -0.29 | -17.47% |
1 Month | 1.36 | 1.87 | 1.1535 | 1.65 | 10,243 | 0.01 | 0.74% |
3 Months | 0.8702 | 1.87 | 0.76 | 1.28 | 10,695 | 0.4998 | 57.44% |
6 Months | 0.859 | 1.87 | 0.6797 | 1.11 | 8,504 | 0.511 | 59.49% |
1 Year | 1.81 | 2.32 | 0.6797 | 1.28 | 8,663 | -0.44 | -24.31% |
3 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 448,026 | -9.63 | -87.55% |
5 Years | 11.00 | 19.56 | 0.6797 | 11.27 | 448,026 | -9.63 | -87.55% |
Protagenic Therapeutics Description
Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. |